Arbor Pharmaceuticals markets branded prescription products for the cardiovascular, hospital, and pediatric markets as well as generic products through its Wilshire division. The company has completed over twenty acquisition, licensing, or product development transactions over the past four years and has multiple products filed with the FDA as well as several branded and generic products in late-stage development. Arbor Pharmaceuticals has approximately 400 employees and is headquartered in Atlanta (www.arborpharma.com).
Arbor Pharmaceuticals was acquired by its current investor group in 2010. Investors include Chief Executive Officer Ed Shutter; Signet Healthcare Partners; JW Asset Management, led by Jason Wild, Chairman of the Board of Arbor; and ARCH Healthcare Fund, led by Allen Chao.
“Arbor is led by an accomplished management team with a track record of building and scaling specialty pharmaceutical platforms. We believe that Arbor, with its diversified product portfolio, late-stage development pipeline, and proven business development acumen, is well positioned for continued growth,” said Ali Satvat, Director on KKR’s Health Care investing team.
KKR makes private equity, fixed income and other investments in companies in North America, Europe, Asia and the Middle East. The firm has $90 billion in assets under management. KKR was founded in 1976 and in addition to its New York headquarters the firm has offices in Menlo Park, San Francisco, Houston, Washington DC, London, Paris, Hong Kong, Tokyo, Beijing, Mumbai, Dubai and Sydney (www.kkr.com).
“We are pleased to be adding KKR, with its extensive industry experience, to our shareholder base. We selected KKR based on a number of factors, including compatibility with Arbor and a shared vision for achieving future growth. This is an important next step as we continue building a fully integrated pharmaceutical company focused on products that improve patients’ lives,” said Mr. Wild.
KKR has a history of investing in and growing health care companies, including Alliance Boots, Biomet, Gland Pharma, HCA, Jazz Pharmaceuticals, and PRA Health Sciences. KKR is funding the Arbor investment primarily from its North America XI private equity fund. The transaction is expected to close early in the first quarter of 2015.
Lazard Middle Market is serving as financial advisor to Arbor.
2014 PEPD • Private Equity’s Leading News Magazine • 12-5-14